May 18, 2026 — AstraZeneca’s Baxfendy (baxdrostat) has been approved in the U.S. as a first-in-class aldosterone synthase inhibitor (ASI) for treating hypertension in combination with other ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
May 18, 2026 — AstraZeneca’s Baxfendy (baxdrostat) has been approved in the U.S. as a first-in-class aldosterone ...
Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...
April 23, 2026 — A new study analyzing data from more than 13,000 patients found that people using the increasingly ...
Jan. 27, 2026 — Cytokinetics, Inc. has announced that Myqorzo (aficamten) is now available for prescription in 5 mg, 10 ...
Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were ...
Sept. 25, 2025 — Kardigan has introduced the three late-stage clinical programs leading its robust pipeline, each ...
Sept. 23, 2025 — CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug ...
Sept. 2, 2025 —Corsera Health, Inc. has announced its launch with a mission to extend healthspan through cardiovascular ...
Aug. 07, 2025 —- New research by European cybersecurity company Modat revealed more than 1.2 million internet-connected ...
July 25, 2025 — Data in recent staffing surveys from the American Society of Radiologic Technologists show that vacancy ...
The American Heart Association recently announced that Dr. Christine E. Seidman, an internationally renowned physician ...
July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...
June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...
June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...
June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...
May 18, 2026